Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

The vasopressin–cAMP–osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Soc Nephrol
Autors principals: Devuyst, Olivier, Chapman, Arlene B., Gansevoort, Ron T., Higashihara, Eiji, Perrone, Ronald D., Torres, Vicente E., Blais, Jaime D., Zhou, Wen, Ouyang, John, Czerwiec, Frank S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2017
Matèries:
Clinical Epidemiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5407721/
https://ncbi.nlm.nih.gov/pubmed/27920153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016040448
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars